Register for Upcoming Webinar on DEC. 8 @ 11AM

2023 China NMPA Bluebook is here:

A US Company Taps Into China’s Market with With Its Skin-Treatment Technology


A US Company Taps Into China’s Market with With Its Skin-Treatment Technology

Sensus Healthcare, a Boca Raton Fla. medical device maker,  has been cleared by CFDA to expand its operations in China, bringing its skin-treatment technology to a country with more than 1.4 billion people.

Specifically, we are talking about Sensus Healthcare’s SRT-100. A device that non-invasively treats skin conditions. i.e.keloids, a type of benign fibrous tissue formed at the area of scars/trauma.

Scientists have found that keloids appear most frequently among those of African, Latin and Asian descent. Since China relaxed its one-child policy, the incidence of keloids has increased due to the prevalence of Cesarean section births. This delivery procedure causes scarring.

Sensus will partner with Chindex Medical Limited. A wholly owned subsidiary of Shanghai-based Fosun Pharma International. The device has been sold in China for treatment of non-melanoma skin cancer.

“CFDA clearance of the SRT-100 for the treatment and prevention of keloids is an important milestone for Sensus, and a step forward for healthcare in China, especially women’s health,” said Sensus CEO Joe Sardano.


About China Med Device, LLC (CMD) CMD provides turn-key solution for Western medtech companies with regulatory and commercialization services. CMD helps its clients accelerate China entry and growth by offering: market Intelligence and research; CFDA regulatory services (premarket submission, clinical evaluation, clinical trial design & management, post market compliance and legal representation), and other commercial services. If you have an inquiry or feedback regarding our services please email us at

Have Questions?

Related Services


Recent Events

Related Posts


Get Updated

Receive Updates in Your Inbox